They’re Coming to America

December 11, 2024

DENVER, Colo., Dec 11, 2024 (247marketnews.com)- Siyata Mobile (NASDAQ: SYTA), AstraZeneca (NASDAQ: AZN), ICU Medical (NASDAQ: ICUI), Nvidia (NASDAQ: NVDA), Taiwan Semiconductor Manufacturing Company (NYSE: TSM), and Advanced Micro Devices (NASDAQ: AMD)

Siyata Mobile’s (NASDAQ: SYTA) plans to relocate its 4G and next-generation 5G PTT device manufacturing operations from China to the United States, in early 2025, is one of the clearest moves yet that aligns with President Elect Donald Trump’s anticipated tariff policies to bolster American manufacturing and reestablish the U.S. as a global manufacturing powerhouse.

Marc Seelenfreund, CEO of Siyata, emphasized the significance of this move, “We are thrilled to bring Siyata’s manufacturing to Texas, at a time when President Trump’s administration is poised to champion domestic manufacturing like never before. This move is more than a business decision; it’s a commitment to the principles of economic patriotism. It not only enhances our ability to serve U.S. customers but positions us as a true partner in America’s resurgence as a manufacturing leader.”

Siyata expects this strategic shift to yield several key benefits, including stronger logistics infrastructure, shortened delivery times, and enhanced appeal to American governmental agencies, first responders, and enterprises that prioritize U.S.-made products.

The tariff threat may already be reflected in the S&P Global U.S. Manufacturing PMI increase from 48.5 in October to 49.7 in November, which is just under the 50 mark that indicates that the sector is contracting, indicated that U.S. manufacturing contraction is at the slowest pace in five months and may be reversing.

The RFK Jr Effect

President-elect Trump plans on nominating Robert F. Kennedy Jr. to lead the Department of Health and Human Services and Kennedy supports onshoring more pharma production.

AstraZeneca (NASDAQ: AZN) and ICU Medical (NASDAQ: ICUI) announced two unrelated onshoring initiatives the week after the election.

AstraZeneca (NASDAQ: AZN) will make a $3.5 billion of capital investment to expand its U.S. research and manufacturing footprint by the end of 2026, including $2 billion of to create over a thousand new, high-skilled jobs contributing to the growth of the U.S. economy.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”

AstraZeneca employs approximately 17,800 workers at 17 R&D, manufacturing, and commercial sites in 12 states.

ICU Medical (NASDAQ: ICUI) and Otsuka Pharmaceutical Factory created a joint venture to provide additional supply chain resiliency and innovation to the North American IV solutions market, which includes an approximately $200 million upfront payment from OPF to ICU Medical at inception and performance-based milestones.

The JV creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and beefs up the North American IV solutions supply chain resiliency.

Shuichi Takagi, President and Representative Director of OPF, commented, “Entering the North American market has always been part of our long-term ambition, and this joint venture with ICU Medical is the perfect way to do that.” Takagi added, “It will allow us to bring our innovative PVC-free technologies—including admixtures, parenteral nutrition in advanced multi-chamber bags, and premix IV antibiotics—to a market with an established customer base.”

“Otsuka’s scale, experience with U.S. partnerships, and demonstrated long-term investment horizon made them the ideal partner,” said Vivek Jain, ICU Medical’s Chief Executive Officer. “Their financial strength and dedication to portfolio expansion will provide the stability and choice the North American market needs,” added Jain. “Through this joint venture, we’re committed to delivering clinical and economic value for ICU Medical customers and giving this critical product category the innovation and attention it deserves.”

CHIPS and Science Act

The CHIPS and Science Act incentivizes onshoring by using taxpayer funds to pay chip manufacturers to set up shop in the U.S.

Nvidia (NASDAQ: NVDA) is reportedly planning to expand its domestic and international footprint and is negotiating with Taiwan Semiconductor Manufacturing Company (NYSE: TSM), to manufacture its Blackwell AI processors at TSMC’s Arizona facility.

TSMC invested billions, including $6.6 billion from the Biden administration’s CHIPS and Science Act, to bring its high-tech manufacturing to the Southwest U.S.

If finalized, Nvidia would join Apple (NASDAQ: AAPL) and Advanced Micro Devices (NASDAQ: AMD), which reportedly already signed a manufacturing agreement to produce chips in the Arizona plant, starting in the first half of 2025.

However, the final packaging of the chips will be completed in Taiwan, which adds layers of inefficiencies an already drawn-out manufacturing process.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SYTA, AZN, ICUI, NVDA, TSM, AMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.